In April 2005, a 72-year-old woman with pulmonary sarcoidosis exhibited focal 18 F-fluoro-2-deoxyglucose ( 18 F-FDG) uptake in her heart on 18 F-FDG positron emission tomography (PET). Although Japanese guidelines for diagnosing cardiac sarcoidosis were not met at this point, electrocardiography, echocardiography, and magnetic resonance imaging became diagnostic for cardiac sarcoidosis 1 year later. In the present case report, the potential of 18 F-FDG PET in the early recognition of cardiac sarcoidosis in comparison with other imaging modalities is discussed.
Introduction
Recent studies have demonstrated promising potential for 18 F-fluoro-2-deoxyglucose ( 18 F-FDG) positron emission tomography (PET) in the diagnosis and assessment of cardiac sarcoidosis (CS). This imaging modality reportedly provides equivalent or better sensitivity for diagnosing CS than magnetic resonance imaging (MRI) and other imaging modalities (1) (2) (3) (4) (5) . The specificity, however, is relatively low and often cases are encountered in which the interpretation of myocardial 18 F-FDG uptake remains inconclusive. We present herein the case of a patient with pulmonary sarcoidosis who had focal 18 F-FDG uptake in the heart on fasting 18 F-FDG PET. CS was diagnosed 1 year later, when findings from electrocardiography (ECG), echocardiography, and MRI proved sufficiently diagnostic. The potential ability and limitations of 18 F-FDG PET for early detection of CS are discussed with reference to this case.
Case Report
In May 2002, a 72-year-old woman with uveitis was referred to our department and was clinically diagnosed with pulmonary sarcoidosis based on bilateral hilar lymphadenopathy on chest radiography, accumulation of 67 Ga-citrate in mediastinal and hilar lymph nodes ("λ pattern"), negative results from the tuberculin skin test, and a high CD4/8 ratio for lymphocytes from bronchoalveolar lavage. In April 2005, complete right bundle-branch block developed on ECG, and 18 F-FDG PET showed focal 18 F-FDG uptake in anteroseptal, anterolateral, and inferior walls of the left ventricle (Fig. 1a) . Serum levels of angiotensin-converting enzyme were elevated to 25.0 IU/L (normal range, 8.3-21.5 IU/L). CS was suspected, but echocardiography, Tc-sestamibi (MIBI) scintigraphy and cardiac MRI revealed no abnormalities (Fig. 1b) . Left ventricular (LV) ejection fraction (LVEF) and LV end-diastolic dimension (LVDd) were both within normal ranges (LVEF, 67%; LVDd, 49 mm). At this point, the criteria of the Japanese Ministry of Health and Welfare Guidelines for Diagnosing Cardiac Sarcoidosis (6) were not met and the patient was followed closely without medical treatment.
In May 2006, she was readmitted to our hospital for newonset left axis deviation. Compared with the previous studies, echocardiography showed thickening and high echo- genicity in the interventricular septum (IVS). LVEF was 65% and LVDd was 45 mm. Focal uptake of 18 F-FDG on LV walls and IVS became slightly more prominent compared with previous findings (Fig. 1c) . Furthermore, cardiac MRI revealed late gadolinium enhancement (LGE) in the anteroseptal and inferior LV walls (Fig. 1d). LGE in the anteroseptal LV wall showed a mid-layer pattern, which is reportedly specific to CS. Coronary heart disease was excluded based on coronary angiography. Pathological examination of mandibular lymph nodes showed non-caseating granulomas, consistent with sarcoidosis. We therefore diagnosed CS based on the Japanese guidelines, and started treatment with 30 mg/day of prednisolone acetate in July 2006. Follow-up 18 F-FDG PET performed 1 month later showed obviously reduced 18 F-FDG uptake in the heart (Fig. 1e) .
Discussion
Whether myocardial 18 F-FDG uptake reflects cardiac sarcoid lesions in patients with sarcoidosis remains to be debated. Indeed, whether cardiac 18 F-FDG uptake in the first evaluation for the present case represented a "true-positive" was uncertain, as echocardiography, Tc-MIBI and MRI showed no abnormalities at that time. The Japanese criteria for diagnosing CS were thus not met at that point. However, abnormal findings were evident 1 year later on ECG, echocardiography and MRI, and 18 F-FDG PET also showed progressed 18 F-FDG uptake in the heart. Reductions in myocardial 18 F-FDG uptake after steroid therapy provided further support to the notion that 18 F-FDG PET at the first work-up had detected early cardiac sarcoid lesions.
A series of case reports have suggested the value of 18 F-FDG PET in detecting cardiac sarcoid lesions (7, 8) , and have indicated favorable capability of 18 F-FDG PET to monitor disease activity of CS during steroid therapy (9-11). For example, Koiwa et al reported an autopsy case demonstrating that 18 F-FDG uptake in the heart corresponds well with pathologically confirmed sarcoid lesions (8). Tadamura et al also documented reduced regional 18 F-FDG uptake in the heart after steroid therapy. In that case report, myocardial 18 F-FDG uptake decreased together with reductions in serum angiotensin-converting enzyme level, as one of the biomarkers reflecting disease activity of sarcoidosis (10) .
Prior studies have shown that the specificity of 18 F-FDG PET for detecting CS (31-91%) is relatively low compared with the sensitivity (82-100%) (1-5) . Possible explanations include nonspecific myocardial uptake of 18 F-FDG in the normal heart. Indeed, physiological 18 F-FDG uptake has been reported in the lateral wall of the left ventricle in healthy individuals under fasting conditions (12, 13 ). Another possibility is early-stage sarcoid lesions that might be present in the heart even in patients who do not meet the diagnostic criteria for CS. This latter possibility might have been applicable to the present case.
Causes of sarcoidosis remain unclear, although several possibilities have been raised (14, 15) . Pathology findings seen in CS range from inflammatory cell infiltration, edema, noncaseating granuloma formation and fibrotic changes to scarring. Among these, 18 F-FDG PET theoretically identifies active lesions. Although 67 Ga scintigraphy and MRI can also theoretically detect inflamed lesions, it is not surprising that imaging modalities based on different rationales provide different cardiac images with a varied pattern. The microangiopathy that commonly develops in sarcoidosis (16) Tc-MIBI scintigraphy may be more suitable for detecting such advanced fibrotic changes (17) .
No pathological verification that 18 F-FDG uptake had depicted early CS lesions was able to be achieved in the present case. While myocardial biopsy might have provided pathological confirmation, the sensitivity of this highly invasive procedure is reportedly less than 20%. In this regard, we have recently reported an autopsy case in which histopathology indicative of sarcoidosis was superimposed on the area showing cardiac 18 F-FDG accumulation (8) . The present findings suggest that 18 F-FDG PET could promise for the early diagnosis of CS. It is recommended that a positive finding on 18 F-FDG PET alone should be interpreted carefully and close follow-up is warranted. More studies are needed to clarify the clinical role of 18 F-FDG PET and other modalities in detecting early CS lesions and achieving better clinical outcomes in patients with sarcoidosis.
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